Q-omics provides the consensus-scored SEC61G-DT profile across patient tissues and cancer cell-line models. SEC61G-DT expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SEC61G-DT is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, SEC61G-DT RNA expression shows 9,950 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KICH, and TGCT as cancer lineages where SEC61G-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC61G-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC61G-DT survival associations across molecular data types. SEC61G-DT RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC61G-DT RNA expression–survival associations across cancer types. High SEC61G-DT expression shows unfavorable associations in KICH and HNSC, but favorable associations in UCS, SKCM, UVM and CHOL. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for SEC61G-DT RNA expression.
This table summarizes SEC61G-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SEC61G-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC61G-DT shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in BLCA, HNSC and STAD. The KICH box plot shows higher SEC61G-DT RNA expression in normal versus tumor tissue (log2 FC = −0.474, t-test p < 0.001).
This table shows molecular features associated with SEC61G-DT in patient tissues and cancer cell lines. In patient samples, SEC61G-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
